WM-A1-3389
WM-A1-3389 is an anti-human IGSF1monoclonal antibody and tumor growth inhibitor. WM-A1-3389 specifically binds to the C-terminus of IGSF1, increases secretion of Granzyme B, IFN?γ, and TNF?α, and inhibits growth of colon cancer or biliary tract cancer in xenogeneic or allogeneic mouse implantation models. WM-A1-3389 can be used for the research of colon cancer, biliary tract cancer, and head and neck cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human
WM-A1-3389 antibody (24 h) significantly increases secretion of Granzyme B, IFN?γ, and TNF?α in a co-culture system of human colon cancer HT29 cells and hPBMCs[1].
WM-A1-3389 antibody (24 h) significantly increases secretion of Granzyme B, IFN?γ, and TNF?α in a co-culture system of human biliary tract cancer Choi-CK cells and hPBMCs[1].
WM-A1-3389 antibody (24 h) significantly increases secretion of Granzyme B, IFN?γ, and TNF?α in a co-culture system of human head and neck cancer FaDu cells and hPBMCs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
WM-A1-3389 antibody (3-30 mg/kg; i.p.; once every three days; two weeks) achieves dose-dependent tumor growth inhibition (50.8% to 68.7%) in C57BL/6N mice bearing MC38 colon cancer allografts[1].
WM-A1-3389 antibody (3-50 mg/kg; i.p.; once every three days; two weeks) achieves dose-dependent tumor growth inhibition (44.9% to 66.0%) in C57BL/6N mice bearing CT26 colon cancer allografts[1].
WM-A1-3389 antibody (30 mg/kg; i.p.; once every three days; three weeks) achieves 58.0 ± 4.3% tumor growth inhibition in humanized mice bearing Choi-CK biliary tract cancer xenografts[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:peripheral blood mononuclear cell humanized mice (6-week-old female; subcutaneous implantation of human colon cancer cell line HT29 cells)[1]
-
Dosage:30 mg/kg
-
Administration:i.p.; once every three days; four weeks
-
Result:Achieved 55.5% tumor growth inhibition relative to the negative control group, with a statistically.
-
Animal Model:C57BL/6N mice (5-week-old female; subcutaneous implantation of mouse colon cancer cell line MC38 cells)[1]
-
Dosage:3 mg/kg; 10 mg/kg; 30 mg/kg
-
Administration:i.p.; once every three days; two weeks
-
Result:Achieved 50.8% tumor growth inhibition relative to the negative control group at 3 mg/kg.
Achieved 58.2% tumor growth inhibition relative to the negative control group at 10 mg/kg.
Achieved 68.7% tumor growth inhibition relative to the negative control group at 30 mg/kg.
Showed a dose-dependent increase in tumor growth inhibition.
-
Animal Model:C57BL/6N mice (5-week-old female; subcutaneous implantation of mouse colon cancer cell line CT26 cells)[1]
-
Dosage:3 mg/kg; 10 mg/kg; 50 mg/kg
-
Administration:i.p.; once every three days; two weeks
-
Result:Achieved 44.9% tumor growth inhibition relative to the negative control group at 3 mg/kg.
Achieved 57.0% tumor growth inhibition relative to the negative control group at 10 mg/kg.
Achieved 66.0% tumor growth inhibition relative to the negative control group at 50 mg/kg.
Showed a dose-dependent increase in tumor growth inhibition.
-
Animal Model:peripheral blood mononuclear cell humanized mice (6-week-old female; subcutaneous implantation of human biliary tract cancer cell line Choi-CK cells)[1]
-
Dosage:30 mg/kg
-
Administration:i.p.; once every three days; three weeks
-
Result:Achieved 58.0% tumor growth inhibition relative to the negative control group, with a statistically.
Q8N6C5
IGSF1
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
[WM-A1-3389]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
WM-A1-3389 Related Classifications
HY-P992021 Related Classifications
Powered by Bioz